Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders

ABSTRACT

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity, in particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.

FIELD

The present invention relates to compositions and formulationscomprising therapeutically or prophylactically active compounds orpharmaceutically acceptable salts thereof, methods for modulating theactivity of Lyn kinase and methods for treating disorders associatedwith Lyn kinase. In particular, the formulation are useful for treatingor preventing diseases and disorders including cardiovascular disease,dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism,metabolic syndrome (i.e., Syndrome X), a peroxisome proliferatoractivated receptor-associated disorder, septicemia, a thromboticdisorder, type II diabetes, cancer, obesity, pancreatitis, hypertension,renal disease, inflammation, or impotence, comprising administering acomposition comprising a therapeutically or prophylactically effectiveamount of a compound of the invention or a pharmaceutically acceptablesalt thereof.

BACKGROUND

Lyn kinase is a member of the src family of non-receptor proteintyrosine kinases that is predominantly expressed in B-lymphoid andmyeloid cells. See, e.g., Briggs S D, Lerner E C, Smithgall T E:Affinity Of Src Family Kinase S H3 Domains For HIV Nef In Vitro Does NotPredict Kinase Activation By Nef In Vivo. Biochemistry 39: 489-495(2000), incorporated herein by reference. Lyn participates in signaltransduction from cell surface receptors that lack intrinsic tyrosinekinase activity. Activation of the lyn kinase activity is necessary forproliferation of CD45+ myeloma cells stimulated by IL-6. See, e.g.,Ishikawa H, Tsuyama N. Abroun S, Liu S, Li F J, Taniguchi O. Kawano M M:Requirements of src family kinase activity associated with CD45 formyeloma cell proliferation by interleukin-6. Blood 99:2172-2178 (2002),incorporated herein by reference. Association of lyn and fyn with theproline-rich domain of glycoprotein VI regulates intracellularsignaling. See, e.g., Suzuki-Inoue K, Tulasne D, Shen Y, Bori-Sanz T.Inoue O, Jung S M, Moroi M, Andrews R K, Berndt M C, Watson S P:Association of Fyn and Lyn with the proline-rich domain of glycoproteinVI regulates intracellular signaling. J. Biol. Chem. 277: 21561-21566(2002), incorporated herein by reference. The lyn/CD22/SHP-1 pathway isimportant in autoimmunity. See, e.g., Blasioli J, Goodnow C C:Lyn/CD22/SHP-1 and their importance in autoimmunity. Curr. Dir.Autoimmun. 5: 151-160 (2002), incorporated herein by reference.

Obesity, hyperlipidemia, and diabetes have been shown to play a causalrole in various disorders including, for example, atheroscleroticcardiovascular diseases, which currently account for a considerableproportion of morbidity in Western society. One human disorder, termed“Syndrome X” or “Metabolic Syndrome,” is manifested by defective glucosemetabolism (e.g., insulin resistance), elevated blood pressure (i.e.,hypertension), and a blood lipid imbalance (i.e., dyslipidemia). Seee.g. Reaven, 1993, Annu. Rev. Med. 44:121-131.

None of the currently commercially available drugs for modulating lynkinase or managing elevated glucose levels have a general utility inregulating lipid, lipoprotein, insulin and glucose levels in the blood.Thus, compounds that have one or more of these utilities are clearlyneeded. Furthermore, there is a clear need to develop safer drugs thatare efficacious at lowering scrum cholesterol, increasing HDL scrumlevels, preventing coronary heart disease, and/or treating existingdisease such as atherosclerosis, obesity, diabetes, and other diseasesthat are affected by glucose metabolism and/or elevated glucose levels.

SUMMARY

The invention encompasses agents that are useful in modulating theactivity of lyn kinase. In particular, the agents useful in modulatingthe activity of lyn kinase include, but are not limited to compositionsand formulations comprising a compound of Formulas I-VII. In anillustrative embodiment, the agents up-regulate the activity and/orexpression of lyn kinase. Thus, surprisingly the compounds of theinvention act as activators or agonists of lyn kinase. Thus, thecompounds of the invention direct the modulation of lyn kinase in theinsulin receptor pathway (i.e., lyn activation has insulin receptoractivation-like activity).

The invention also encompasses methods for treating or preventing adisease or disorder including, but not limited to, cardiovasculardisease, dyslipidemia, reducing fat depot levels, dyslipoproteinemia, adisorder of glucose metabolism (i.e., elevated blood glucose levels),metabolic syndrome (i.e., Syndrome X), a PPAR-associated disorder,septicemia, a thrombotic disorder, type II diabetes, cancer, obesity,pancreatitis, hypertension, a renal disease, inflammation, and impotencecomprising administering to a subject, preferably a mammal, in needthereof a therapeutically or prophylactically effective amount of acomposition or formulation comprising a compound of the invention.

The invention further encompasses methods for reducing blood glucoselevels, reducing fat depot levels and for treating or preventing acardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder ofglucose metabolism, metabolic syndrome (i.e., Syndrome X), aPPAR-associated disorder, septicemia, a thrombotic disorder, type IIdiabetes, obesity, pancreatitis, hypertension, a renal disease,inflammation, and impotence, which comprises administering to a mammalin need of such treatment or prevention a therapeutically orprophylactically effective amount of a composition comprising a compoundof Formula I-VI, or a pharmaceutically acceptable salt or prodrugthereof, and a pharmaceutically acceptable vehicle.

In a preferred embodiment, the composition comprising a compound of theinvention are for the use in treating or preventing metabolic syndromeor Syndrome X or the treatment of disorders associated with thesesyndromes including, but not limited to, obesity, prediabetes, and typeII diabetes as well as complications of obesity and diabetes.Complications of obesity include, but are not limited to,hypercholesterolemia, hypertension, and coronary heart disease.Complications of diabetes include, but are not limited to, diabeticneuropathy, diabetic retinopathy, erectile dysfunction, and kidneydisease.

As described herein, the compositions that are useful in the methods ofthe invention encompass compounds of Formulas I-VII.

In one embodiment, the invention encompasses compositions comprising acompound of formula (I):

or pharmaceutically acceptable salts and prodrugs thereof, wherein R¹ isan alkyl group; X is a halogen; Y is O, S, or NH; Z is O or S; n is aninteger from 0 to 5 and m is an integer from 0 to 5, wherein m+n is lessthan or equal to 5.

In one embodiment, the alkyl group is methyl and n is 1. In anotherembodiment, the halogen is chlorine and m is 1. In another embodiment, Yis O. In another embodiment, the Z is O.

In a preferred embodiment, R₁ is methyl, Y is O, Z is O, n is 1, and mis 0, more preferably R₁ is in the meta position.

In another preferred embodiment, X is chlorine, Y is O, Z is O, n is 0,and m is 1, more preferably X is in the meta position. In anotherpreferred embodiment, the mammal is a human. In another preferredembodiment, the effective amount is from about 0.1 mg to about 100mg/kg, preferably the administration is oral.

In another embodiment, the invention encompasses compositions comprisinga compound of formula (II):

or pharmaceutically acceptable salts and prodrugs thereof, wherein R¹ isan alkyl group; X is a halogen; n is an integer from 0 to 5 and m is aninteger from 0 to 5, wherein m+n is less than or equal to 5.

In yet another embodiment, the invention encompasses compositionscomprising a compound of formula (III):

or pharmaceutically acceptable salts and prodrugs thereof, wherein R¹ isan alkyl group and n is an integer from 0 to 5.

In another embodiment, the invention encompasses compositions comprisinga compound of formula (III):

or pharmaceutically acceptable salts and prodrugs thereof, wherein X isa halogen and m is an integer from 0 to 5.

In another embodiment, the invention encompasses compositions comprisinga compound of formula (V):

or pharmaceutically acceptable salts and prodrugs thereof.

In another embodiment, the invention encompasses compositions comprisinga compound of formula (VI):

or pharmaceutically acceptable salts and prodrugs thereof.

The present invention may be understood more fully by reference to thefigures, detailed description, and examples, which are intended toexemplify non-limiting embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates oral glucose tolerance of Compound 102 byadministering Compound 102 once at the indicated doses prior to glucoseadministration. Blood glucose levels were measured at the indicatedtimes.

FIG. 2 illustrates oral glucose tolerance of Compound 102 byadministering Compound 102 four times at 30 minute intervals at theindicated doses prior to glucose administration. Blood glucose levelswere measured at the indicated times.

FIG. 3 illustrates oral glucose tolerance of Compound 102 byadministering Compound 105 once at the indicated doses prior to glucoseadministration. Blood glucose levels were measured at the indicatedtimes.

FIG. 4 illustrates weight gain of animals administered Compound 102.Animals were weighed every other day for the duration of the study.

FIG. 5 illustrates food intake of animals administered Compound 102.Food weight was monitored every day beginning on day 14 of the westerndiet.

FIG. 6 illustrates fat pad weights of animals administered Compound 102.At the end of the Western diet study (day 31), animals were sacrificedand fat pads weighed

FIG. 7 illustrates leptin levels of animals administered Compound 102.Mice on western diet were analyzed for leptin on days 7 and 14 of thediet.

FIG. 8 illustrates weight changes in Db/Db mice, which were dosed withCompound 102 at the indicated doses bid (twice/day). Weight changes andfood intake were monitored over the course of the study (28 days).Compound 102 significantly lowered weight gain without affecting foodintake.

FIG. 9 illustrates reduction in glucose levels in db/db mice after anacute injection of Compound 102. The glucose levels were measured afterthe first treatment of the chronic study. Glucose levels were measured 2hrs after drug administration.

FIG. 10 illustrates reduction in weight gain in Db/Db mice administeredCompound 102 without affecting food intake.

FIG. 11 illustrates reduction is blood glucose levels in Zucker Ratsadministered Compound 102 and challenged with a high oral glucosesolution. At 12 weeks of age, Zucker rats were administered Compound 102at a concentration of 30 mg/kg (ip). Blood glucose levels were measured30 minutes after administration. Forty-five minutes after drug.

FIG. 12 illustrates increased in vitro activity in the Lyn Kinase enzymedemonstrated by Compound 102.

DETAILED DESCRIPTION Definitions

As used herein and unless otherwise indicated, the phrase “alteringlipid metabolism” indicates an observable (i.e., measurable) change inat least one aspect of lipid metabolism including, but not limited to,total blood lipid content, blood HDL cholesterol, blood LDL cholesterol,blood VLDL cholesterol, blood triglyceride, blood Lp(a), blood apo A-I,blood apo E or blood non-esterified fatty acids.

As used herein and unless otherwise indicated, the phrase “alteringglucose metabolism” indicates an observable (i.e., measurable) change inat least one aspect of glucose metabolism including, but not limited to,total blood glucose content, blood insulin, the blood insulin to bloodglucose ratio, insulin sensitivity, or oxygen consumption.

As used herein and unless otherwise indicated, the term “alkoxy group”means an —O— alkyl group, wherein alkyl is as defined herein. An alkoxygroup can be unsubstituted or substituted with one or two suitablesubstituents. Preferably, the alkyl chain of an alkyloxy group is from 1to 6 carbon atoms in length, referred to herein, for example, as“(C₁-C₆)alkoxy.”

As used herein and unless otherwise indicated, the term “alkyl” or“alkyl group” means a saturated, monovalent unbranched or branchedhydrocarbon chain. Examples of alkyl groups include, but are not limitedto, (C₁-C₆)alkyl groups, such as methyl, ethyl, propyl, isopropyl,2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl,2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl,isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longeralkyl groups, such as heptyl, and octyl. An alkyl group can beunsubstituted or substituted with one or two suitable substituents.

As used herein and unless otherwise indicated, the term “alkenyl group”means a monovalent unbranched or branched hydrocarbon chain having oneor more double bonds therein. The double bond of an alkenyl group can beunconjugated or conjugated to another unsaturated group. Suitablealkenyl groups include, but are not limited to (C₂-C₆)alkenyl groups,such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl,pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl,4-(2-methyl-3-butene)-pentenyl. An alkenyl group can be unsubstituted orsubstituted with one or two suitable substituents.

As used herein and unless otherwise indicated, the term “alkynyl group”means monovalent unbranched or branched hydrocarbon chain having one ormore triple bonds therein. The triple bond of an alkynyl group can beunconjugated or conjugated to another unsaturated group. Suitablealkynyl groups include, but are not limited to, (C₂-C₆)alkynyl groups,such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl,4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl. Analkynyl group can be unsubstituted or substituted with one or twosuitable substituents.

As used herein and unless otherwise indicated, the term “aryl group”means a monocyclic or polycyclic-aromatic radical comprising carbon andhydrogen atoms. Examples of suitable aryl groups include, but are notlimited to, phenyl, tolyl, anthacenyl, fluorenyl, indenyl, azulenyl, andnaphthyl, as well as benzo-fused carbocyclic moieties such as5,6,7,8-tetrahydronaphthyl. An aryl group can be unsubstituted orsubstituted with one or two suitable substituents. Preferably, the arylgroup is a monocyclic ring, wherein the ring comprises 6 carbon atoms,referred to herein as “(C₆)aryl.”

As used herein and unless otherwise indicated, the term “aryloxy group”means an —O— aryl group, wherein aryl is as defined herein. An aryloxygroup can be unsubstituted or substituted with one or two suitablesubstituents. Preferably, the aryl ring of an aryloxy group is amonocyclic ring, wherein the ring comprises 6 carbon atoms, referred toherein as “(C₆)aryloxy.”

As used herein, the term “benzyl” means —CH₂-phenyl.

As used herein, the term “carbonyl” group is a divalent group of theformula —C(O)—.

As used herein and unless otherwise indicated, the term “compounds ofthe invention” means, collectively, the compounds of formulas I, II,III, IV, V, and VI and pharmaceutically acceptable salts thereof. Thecompounds of the invention are identified herein by their chemicalstructure and/or chemical name. Where a compound is referred to by botha chemical structure and a chemical name, and that chemical structureand chemical name conflict, the chemical structure is determinative ofthe compound's identity. The compounds of the invention may contain oneor more chiral centers and/or double bonds and, therefore, exist asstereoisomers, such as double-bond isomers (i.e., geometric isomers),enantiomers, or diastereomers. According to the invention, the chemicalstructures depicted herein, and therefore the compounds of theinvention, encompass all of the corresponding compound's enantiomers andstereoisomers, that is, both the stereomerically pure form (e.g.,geometrically pure, enantiomerically pure, or diastereomerically pure)and enantiomeric and stereoisomeric mixtures. Enantiomeric andstereoisomeric mixtures can be resolved into their component enantiomersor stereoisomers by well known methods, such as chiral-phase gaschromatography, chiral-phase high performance liquid chromatography,crystallizing the compound as a chiral salt complex, or crystallizingthe compound in a chiral solvent. Enantiomers and stereoisomers can alsobe obtained from stereomerically- or enantiomerically-pureintermediates, reagents, and catalysts by well known asymmetricsynthetic methods.

As used herein and unless otherwise indicated, the term “cycloalkylgroup” means a monocyclic or polycyclic saturated ring comprising carbonand hydrogen atoms and having no carbon-carbon multiple bonds. Examplesof cycloalkyl groups include, but are not limited to, (C₃-C₇)cycloalkylgroups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, andcycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkylgroup can be unsubstituted or substituted by one or two suitablesubstituents. Preferably, the cycloalkyl group is a monocyclic ring orbicyclic ring.

As used herein, the terms “diabetes” and “type II diabetes” are usedinterchangeably and include, but are not limited to, non-insulindependent diabetes mellitus, diabetes insipidus, and are related toinsulin resistance (i.e., lack of the ability of the body to respond toinsulin appropriately) and is often accompanied by related complicationsincluding, for example, obesity and high cholesterol.

As used herein, the term “halogen” means fluorine, chlorine, bromine, oriodine. Correspondingly, the meaning of the terms “halo” and “Hal”encompass fluoro, chloro, bromo, and iodo.

As used herein and unless otherwise indicated, the term “heteroarylgroup” means a monocyclic- or polycyclic aromatic ring comprising carbonatoms, hydrogen atoms, and one or more heteroatoms, preferably 1 to 3heteroatoms, independently selected from nitrogen, oxygen, and sulfur.Illustrative examples of heteroaryl groups include, but are not limitedto, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl,pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl,pyrimidinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, furyl,phienyl, isoxazolyl, and oxazolyl. A heteroaryl group can beunsubstituted or substituted with one or two suitable substituents.Preferably, a heteroaryl group is a monocyclic ring, wherein the ringcomprises 2 to 5 carbon atoms and 1 to 3 heteroatoms, referred to hereinas “(C₂-C₅)heteroaryl.”

As used herein and unless otherwise indicated, the term“heterocycloalkyl group” means a monocyclic or polycyclic ringcomprising carbon and hydrogen atoms and at least one heteroatom,preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, andsulfur, and having no unsaturation. Examples of heterocycloalkyl groupsinclude pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl,piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino,and pyranyl. A heterocycloalkyl group can be unsubstituted orsubstituted with one or two suitable substituents. Preferably, theheterocycloalkyl group is a monocyclic or bicyclic ring, morepreferably, a monocyclic ring, wherein the ring comprises from 3 to 6carbon atoms and form 1 to 3 heteroatoms, referred to herein as(C₁-C₆)heterocycloalkyl.

As used herein and unless otherwise indicated, the term “heterocyclicradical” or “heterocyclic ring” means a heterocycloalkyl group or aheteroaryl group.

As used herein and unless otherwise indicated, the term “hydrocarbylgroup” means a monovalent group selected from (C₁-C₈)alkyl,(C₂-C₈)alkenyl, and (C₂-C₈)alkynyl, optionally substituted with one ortwo suitable substituents. Preferably, the hydrocarbon chain of ahydrocarbyl group is from 1 to 6 carbon atoms in length, referred toherein as “(C₁-C₆)hydrocarbyl.”

When administered to a mammal (e.g., to an animal for veterinary use orto a human for clinical use) the compounds of the invention areadministered in isolated form. As used herein, “isolated” means that thecompounds of the invention are separated from other components of either(a) a natural source, such as a plant or cell, preferably bacterialculture, or (b) a synthetic organic chemical reaction mixture,preferably, via conventional techniques, the compounds of the inventionare purified. As used herein, “purified” means that when isolated, theisolate contains at least 90% preferably at least 95%, more preferablyat least 98%, and most preferably at least 99% of a compound of theinvention by weight of the isolate.

As used herein and unless otherwise indicated, the term “lyn kinaserelated disorder” refers to any disorder in a mammal including humans,associated with the altered expression and/or activity of lyn kinaseincluding, but not limited to, cardiovascular disease, dyslipidemia,reducing fat depot levels, dyslipoproteinemia, a disorder of glucosemetabolism (i.e., elevated blood glucose levels), metabolic syndrome(i.e., Syndrome X), a PPAR-associated disorder, septicemia, a thromboticdisorder, diabetes, obesity, pancreatitis, hypertension, a renaldisease, inflammation, and impotence.

As used herein and unless otherwise indicated, the term “modulate”refers to a change in the expression and/or activity of a protein,preferably an enzyme, more preferably lyn kinase. In an illustrativeembodiment, “modulate” refers to increase or decrease the expressionand/or activity of a protein, preferably an enzyme, more preferably lynkinase.

The phrase “pharmaceutically acceptable salt(s),” as used hereinincludes but is not limited to salts of acidic or basic groups that maybe present in compounds used in the present compositions. Compoundsincluded in the present compositions that are basic in nature arecapable of forming a wide variety of salts with various inorganic andorganic acids. The acids that may be used to prepare pharmaceuticallyacceptable acid addition salts of such basic compounds are those thatform non-toxic acid addition salts, i.e., salts containingpharmacologically acceptable anions including, but not limited to,sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide,hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate,isonicotinate, acetate, lactate, salicylate, citrate, acid citrate,tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate,succinate, maleate, gentisinate, fumarate, gluconate, glucaronate,saccharate, formate, benzoate, glutamate, methanesulfonate,ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e.,1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds includedin the present compositions that include an amino moiety may formpharmaceutically acceptable salts with various amino acids, in additionto the acids mentioned above. Compounds, included in the presentcompositions, that are acidic in nature are capable of forming basesalts with various pharmacologically acceptable cations. Examples ofsuch salts include alkali metal or alkaline earth metal salts and,particularly, calcium, magnesium, sodium lithium, zinc, potassium, andiron salts.

The term “phenyl” means —C₆H₅. A phenyl group can be unsubstituted orsubstituted with one or two suitable substituents.

As used herein, “pre-diabetes” refers to symptoms of diabetes whereinthe patient exhibits elevated glucose levels but the full onset ofdisorders associated with type II diabetes has not yet manifesteditself.

As used herein, a “suitable substituent” means a group that does notnullify the synthetic or pharmaceutical utility of the compounds of theinvention or the intermediates useful for preparing them. Examples ofsuitable substituents include, but are not limited to: (C₁-C₈)alkyl;(C₁-C₈)alkenyl; (C₁-C₈)alkynyl; (C₆)aryl; (C₃-C₅)heteroaryl;(C₃-C₇)cycloalkyl; (C₁-C₈)alkoxy; (C₆)aryloxy; —CN; —OH; oxo; halo,—NO₂, —CO₂H; —NH₂; —NH((C₁-C₈)alkyl); —N((C₁-C₈)alkyl)₂; —NH((C₆)aryl);—N((C₆)aryl)₂; —CHO; —CO((C₁-C₈)alkyl); —CO((C₆)aryl);—CO₂((C₁-C₈)alkyl); and —CO₂((C₆)aryl). One of skill in art can readilychoose a suitable substituent based on the stability and pharmacologicaland synthetic activity of the compound of the invention.

As used herein and unless otherwise indicated, the phrase“therapeutically effective amount” of a composition of the invention ismeasured by the therapeutic effectiveness of a compound of theinvention, wherein at least one adverse effect of a disorder isameliorated or alleviated. In one embodiment, the phrase“therapeutically effective amount” of a composition of the invention ismeasured by the therapeutic effectiveness of a compound of the inventionto alter the expression and/or activity of lyn kinase including, but notlimited to up- and down-regulation of this protein. Surprisingly, theinventors have found that therapeutically effective amounts of thecompounds of the invention up-regulate the expression and/or activity oflyn kinase.

Compounds

As set forth herein, the invention encompasses methods for treating orpreventing a cardiovascular disease, dyslipidemia, dyslipoproteinemia, adisorder of glucose metabolism, Syndrome X, a PPAR-associated disorder,septicemia, a thrombotic disorder, type II diabetes, obesity,pancreatitis, hypertension, a renal disease, inflammation, andimpotence, which comprises administering to a mammal in need of suchtreatment or prevention a therapeutically or prophylactically effectiveamount of a composition comprising a compound of Formula I-VII, or apharmaceutically acceptable salt or prodrug thereof, and apharmaceutically acceptable vehicle.

The invention encompasses methods of treating or preventing diseases anddisorders described herein by administering a composition or formulationcomprising a compound of Formula VII:

wherein each of R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are independently ahydrogen, alkoxy, alkyl, alkenyl, alkynyl, aryl, aryloxy, benzyl,cycloalkyl, halogen, heteroaryl, heterocycloalkyl, —CN, —OH, —NO₂, —CF₃,—CO₂H, —CO₂alkyl, or —NH₂;

R₈ is an alkyl or hydrogen;

X is O, S, NH, or N-akyl; and

Z is O or S.

In one illustrative embodiment, R₈ is alkyl, preferably methyl.

In another illustrative embodiment, R₈ is a hydrogen.

In another illustrative embodiment, X is oxygen.

In another illustrative embodiment, Z is oxygen.

In another illustrative embodiment, at least one of R₂-R₆ is alkyl,preferably methyl.

In another illustrative embodiment, at least one of R₂-R₆ is halogen,preferably chloro.

In another illustrative embodiment, at least one of R₂-R₆ is —CN.

In another illustrative embodiment, at least one of R₂-R₆ is —OH.

In another illustrative embodiment, at least one of R₂-R₆ is —NO₂.

In another illustrative embodiment, at least one of R₂-R₄ is —CF₃.

In another illustrative embodiment, at least one of R₂-R₆ is CO₂H.

In another illustrative embodiment, at least one of R₂-R₆ is —NH₂.

In another illustrative embodiment, at least one of R₂-R₆ is -alkoxy.

In another illustrative embodiment, R₂ is alkyl, preferably methyl andeach of R₁, and R₃-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₂ is a halogen, preferably chloro,and each of R₁, and R₃-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₃ is alkyl, preferably methyl andeach of R₁, R₂ and R₄-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₃ is a halogen, preferably chloro,and each of R₁, R₂, and R₄-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₄ is alkyl, preferably methyl andeach of R₁-R₃ and R₅-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₄ is a halogen, preferably chloro,and each of R₁-R₃, and R₅-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₅ is —CF₃, and each of R₁-R₄ andR₆-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₅ —NH₂, and each of R₁-R₄ and R₆-R₈is hydrogen and X and Z are O.

In another illustrative embodiment, R₆ is —CF₃, and each of R₁-R₅ andR₇-R₈ is hydrogen and X and Z are O.

In another illustrative embodiment, R₆ is —NH₂ and each of R₁-R₅ andR₇-R₈ is hydrogen and X and Z are O.

Illustrative examples of compounds that are encompassed by FormulasI-VII and that are useful in the methods of the invention include, butare not limited to:

It will be understood that above compounds are illustrative only and notintended to limit the scope of the claims to only those compounds.

The compounds of the invention can be synthesized by organic chemistrytechniques known to those of ordinary skill in the art, for example asdescribed in U.S. Pat. No. 3,922,345, which is incorporated herein byreference in its entirety.

Therapeutic Uses of the Compounds

The invention encompasses compounds that are effective in modulating theexpression and/or activity of lyn kinase both in vitro and in vivo. Theinventors have surprisingly found that the compounds of the inventionare effective in modulating lyn kinase. Without being limited by theory,it is believed that modulation of lyn kinase expression and/or activityis useful in treating or preventing a disorder associated with abnormalblood glucose levels, weight gain, or fat depot levels. The inventionfurther encompasses compositions and formulations comprising one or morecompounds that are useful in modulating lyn kinase activity. Theinvention also encompasses methods of modulating lyn kinase activitycomprising administering subject, preferably to a mammal including ahuman in need of said treatment or prevention a therapeutically orprophylactically effective amount of an agent described herein tomodulate the activity of lyn kinase. In an illustrative embodiment, theagent for modulating lyn kinase activity is a compound of the invention.

In one embodiment, a composition of the invention comprising a compoundof the invention and a pharmaceutically acceptable vehicle, isadministered to a mammal, preferably a human, with a cardiovasculardisease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucosemetabolism, metabolic syndrome (i.e., Syndrome X), a PPAR-associateddisorder, septicemia, a thrombotic disorder, type II diabetes, obesity,pancreatitis, hypertension, a renal disease, inflammation, or impotence.

In one embodiment, “treatment” or “treating” refers to an ameliorationof a disease or disorder, or at least one discernible symptom thereof,preferably associated with lyn kinase. In another embodiment,“treatment” or “treating” refers to an amelioration of at least onemeasurable physical parameter, not necessarily discernible by thepatient. In yet another embodiment, “treatment” or “treating” refers toinhibiting the progression of a disease or disorder, either physically,e.g., stabilization of a discernible symptom, physiologically, e.g.,stabilization of a physical parameter, or both. In yet anotherembodiment, “treatment” or “treating” refers to delaying the onset of adisease or disorder.

In certain embodiments, the compositions of the invention areadministered to a patient, preferably a human, as a preventative measureagainst such diseases. As used herein, “prevention” or “preventing”refers to a reduction of the risk of acquiring a given disease ordisorder. In a preferred mode of the embodiment, the compositions of thepresent invention are administered as a preventative measure to apatient, preferably a human having a genetic predisposition to acardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorderof glucose metabolism, metabolic syndrome (i.e., Syndrome X), aPPAR-associated disorder, septicemia, a thrombotic disorder, type IIdiabetes, obesity, pancreatitis, hypertension, a renal disease,inflammation, or impotence. Examples of such genetic predispositionsinclude, but are not limited to, the ε4 allele of apolipoprotein E; aloss of function or null mutation in the lipoprotein lipase gene codingregion or promoter (e.g., mutations in the coding regions resulting inthe substitutions D9N and N291 S; for a review of genetic mutations inthe lipoprotein lipase gene that increase the risk of cardiovasculardiseases, dyslipidemias and dyslipoproteinemias, see, e.g., Hayden andMa, 1992, Mol. Cell Biochem. 113:171-176); and familial combinedhyperlipidemia and familial hypercholesterolemia.

In another illustrative mode of the embodiment, the compositions of theinvention are administered as a preventative measure to a subject havinga non-genetic predisposition to a cardiovascular disease, adyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism,metabolic syndrome (i.e., Syndrome X), a PPAR-associated disorder,septicemia, a thrombotic disorder, type II diabetes, obesity,pancreatitis, hypertension, a renal disease, inflammation, or impotence.Examples of such non-genetic predispositions include, but are notlimited to, cardiac bypass surgery and percutaneous transluminalcoronary angioplasty, which often lead to restenosis, an acceleratedform of atherosclerosis; diabetes in women, which often leads topolycystic ovarian disease; and cardiovascular disease, which oftenleads to impotence. Accordingly, the compositions of the invention maybe used for the prevention of one disease or disorder and concurrentlytreating another (e.g., prevention of polycystic ovarian disease whiletreating diabetes; prevention of impotence while treating acardiovascular disease). In one particular embodiment, the methods ofthe invention do not encompass treating or preventing asthma.

Cardiovascular Diseases for Treatment or Prevention

The present invention provides methods for the treatment or preventionof a cardiovascular disease, comprising administering to a patient atherapeutically effective amount of a composition comprising a compoundof the invention and a pharmaceutically acceptable vehicle. In someembodiments, the cardiovascular disease is associated withabnormal/altered lyn kinase activity and/or expression. As used herein,the term “cardiovascular diseases” refers to diseases of the heart andcirculatory system. These diseases are often associated withdyslipoproteinemias and/or dyslipidemias. Cardiovascular diseases, whichthe compositions of the invention are useful for preventing or treatinginclude, but are not limited to, arteriosclerosis; atherosclerosis;stroke; ischemia; endothelium dysfunctions, in particular thosedysfunctions affecting blood vessel elasticity; peripheral vasculardisease; coronary heart disease; myocardial infarcation; cerebralinfarction and restenosis.

Dyslipidemias for Treatment or Prevention

The present invention provides methods for the treatment or preventionof a dyslipidemia comprising administering to a patient atherapeutically effective amount of a composition comprising a compoundof the invention and a pharmaceutically acceptable vehicle. In someembodiments, the dyslipidemia is associated with abnormal/altered lynkinase activity and/or expression. As used herein, the term“dyslipidemias” refers to disorders that lead to or are manifested byaberrant levels of circulating lipids. To the extent that levels oflipids in the blood are too high, the compositions of the invention areadministered to a patient to restore normal levels. Normal levels oflipids are reported in medical treatises known to those of skill in theart. For example, recommended blood levels of LDL, HDL, freetriglycerides and others parameters which are used to diagnosedyslipidemia can be found at the web site of the American HeartAssociation and that of the National Cholesterol Education Program ofthe National Heart, Lung and Blood Institute. At the present time, therecommended level of HDL cholesterol in the blood is above 35 mg/dL: therecommended level of LDL cholesterol in the blood is below 130 mg/dL;the recommended LDL:HDL cholesterol ratio in the blood is below 5:1,ideally 3.5:1; and the recommended level of free triglycerides in theblood is less than 200 mg/dL.

Dyslipidemias which the compositions of the present invention are usefulfor preventing or treating include but are not limited to hyperlipidemiaand low blood levels of high density lipoprotein (HDL) cholesterol. Incertain embodiments, the hyperlipidemia for prevention or treatment bythe compounds of the present invention is familial hypercholesterolemia;familial combined hyperlipidemia; reduced or deficient lipoproteinlipase levels or activity, including reductions or deficienciesresulting from lipoprotein lipase mutations; hypertriglyceridemia;hypercholesterolemia; high blood levels of ketone bodies (e.g., β-OHbutyric acid); high blood levels of Lp(a) cholesterol; high blood levelsof low density lipoprotein (LDL) cholesterol; high blood levels of verylow density lipoprotein (VLDL) cholesterol and high blood levels ofnon-esterified fatty acids.

The present invention further provides methods for altering lipidmetabolism in a patient, for example, reducing LDL in the blood of apatient, reducing free triglycerides in the blood of a patient,increasing the ratio of HDL to LDL in the blood of a patient, andinhibiting saponified and/or non-saponified fatty acid synthesis, saidmethods comprising administering to the patient a composition comprisinga compound of the invention in an amount effective alter lipidmetabolism.

Dyslipoproteinemias for Treatment or Prevention

The present invention provides methods for the treatment or preventionof a dyslipoproteinemia comprising administering to a patient atherapeutically effective amount of a composition comprising a compoundof the invention and a pharmaceutically acceptable vehicle. As usedherein, the term “dyslipoproteinemias” refers to disorders that lead toor are manifested by aberrant levels of circulating lipoproteins. To theextent that levels of lipoproteins in the blood are too high, thecompositions of the invention are administered to a patient to restorenormal levels. Conversely, to the extent that levels of lipoproteins inthe blood are too low, the compositions of the invention areadministered to a patient to restore normal levels. Normal levels oflipoproteins are reported in medical treatises known to those of skillin the art.

Dyslipoproteinemias, which the compositions of the present invention areuseful for preventing or treating include, but are not limited to, highblood levels of LDL; high blood levels of apolipoprotein B (apo B); highblood levels of Lp(a); high blood levels of apo(a); high blood levels ofVLDL; low blood levels of HDL; reduced or deficient lipoprotein lipaselevels or activity, including reductions or deficiencies resulting fromlipoprotein lipase mutations; hypoalphalipoproteinemia; lipoproteinabnormalities associated with diabetes; lipoprotein abnormalitiesassociated with type II diabetes, obesity; lipoprotein abnormalitiesassociated with Alzheimers Disease; and familial combinedhyperlipidemia.

The present invention further provides methods for reducing apo C-IIlevels in the blood of a patient; reducing apo C-III levels in the bloodof a patient; elevating the levels of HDL associated proteins, includingbut not limited to apo A-I, apo A-II, apo A-IV and apo E in the blood ofa patient; elevating the levels of apo E in the blood of a patient, andpromoting clearance of triglycerides from the blood of a patient, saidmethods comprising administering to the patient a composition comprisinga compound of the invention in an amount effective to bring about saidreduction, elevation or promotion, respectively.

Glucose Metabolism Disorders for Treatment or Prevention

The present invention provides methods for the treatment or preventionof a glucose metabolism disorder, comprising administering to a patienta therapeutically effective amount of a composition comprising acompound of the invention and a pharmaceutically acceptable vehicle. Asused herein, the term “glucose metabolism disorders” refers to disordersthat lead to or are manifested by aberrant glucose storage and/orutilization. To the extent that indicia of glucose metabolism (i.e.,blood insulin, blood glucose) are too high, the compositions of theinvention are administered to a patient to restore normal levels.Conversely, to the extent that indicia of glucose metabolism are toolow, the compositions of the invention are administered to a patient torestore normal levels. Normal indicia of glucose metabolism are reportedin medical treatises known to those of skill in the art. In someembodiments, the glucose metabolism disorder is associated withabnormal/altered lyn kinase activity and/or expression.

Glucose metabolism disorders which the compositions of the presentinvention are useful for preventing or treating include but are notlimited to impaired glucose tolerance; insulin resistance; insulinresistance related breast, colon or prostate cancer; diabetes, includingbut not limited to non-insulin dependent diabetes mellitus (NIDDM),insulin dependent diabetes mellitus (IDDM), gestational diabetesmellitus (GDM), and maturity onset diabetes of the young (MODY);pancreatitis; hypertension; and high levels of blood insulin and/orglucose.

The present invention further provides methods for altering glucosemetabolism in a patient, for example to increase insulin sensitivityand/or oxygen consumption of a patient, said methods comprisingadministering to the patient a composition comprising a compound of theinvention in an amount effective to alter glucose metabolism.

PPAR Associated Disorders for Treatment or Prevention

The present invention provides methods for the treatment or preventionof a peroxisome proliferative activated receptor (“PPAR”)-associateddisorder, comprising administering to a patient a therapeuticallyeffective amount of a composition comprising a compound of the inventionand a pharmaceutically acceptable vehicle. In some embodiments, thePPAR-associated disorder is associated with abnormal/altered lyn kinaseactivity and/or expression. As used herein, “treatment or prevention ofPPAR associated disorders” encompasses treatment or prevention ofrheumatoid arthritis; multiple sclerosis; psoriasis; inflammatory boweldiseases; breast; colon or prostate cancer; low levels of blood HDL; lowlevels of blood, lymph and/or cerebrospinal fluid apo E; low blood,lymph and/or cerbrospinal fluid levels of apo A-I; high levels of bloodVLDL; high levels of blood LDL; high levels of blood triglyceride; highlevels of blood apo B; high levels of blood apo C-III and reduced ratioof post-heparin hepatic lipase to lipoprotein lipase activity. HDL maybe elevated in lymph and/or cerebral fluid.

Renal Diseases for Treatment or Prevention

The present invention provides methods for the treatment or preventionof a renal disease, comprising administering to a patient atherapeutically effective amount of a composition comprising a compoundof the invention and a pharmaceutically acceptable vehicle. In someembodiments, the renal disease is associated with abnormal/altered lynkinase activity and/or expression. Renal diseases that can be treated bythe compounds of the present invention include glomerular diseases(including but not limited to acute and chronic glomerulonephritis,rapidly progressive glomerulonephritis, nephrotic syndrome, focalproliferative glomerulonephritis, glomerular lesions associated withsystemic disease, such as systemic lupus erythematosus, Goodpasture'ssyndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease,and chronic inflammatory diseases), tubular diseases (including but notlimited to acute tubular necrosis and acute renal failure, polycysticrenal diseasemedullary sponge kidney, medullary cystic disease,nephrogenic diabetes, and renal tubular acidosis), tubulointerstitialdiseases (including but not limited to pyelonephritis, drug and toxininduced tubulointerstitial nephritis, hypercalcemic nephropathy, andhypokalemic nephropathy) acute and rapidly progressive renal failure,chronic renal failure, nephrolithiasis, or tumors (including but notlimited to renal cell carcinoma and nephroblastoma). In a most preferredembodiment, renal diseases that are treated by the compounds of thepresent invention are vascular diseases, including but not limited tohypertension, nephrosclerosis, microangiopathic hemolytic anemia,atheroembolic renal disease, diffuse cortical necrosis, and renalinfarcts.

Treatment or Prevention of Metabolic Syndrome

As used herein, “treatment or prevention of Syndrome X or MetabolicSyndrome” encompasses treatment or prevention of a symptom associatedwith metabolic syndrome including, but not limited to, impaired glucosetolerance, hypertension and dyslipidemia and/or dyslipoproteinemia. Insome embodiments, the metabolic syndrome is associated withabnormal/altered lyn kinase activity and/or expression

Metabolic syndrome is characterized by a group of metabolic risk factorsin a person. Risk factors that are associated with metabolic syndromethat can be treated or prevented by administering a compositioncomprising a compound of the invention include, but are not limited to,central obesity (i.e., excessive fat tissue in and around the abdomen);atherogenic dyslipidemia (blood fat disorders—mainly high triglyceridesand low HDL cholesterol—that foster plaque buildups in artery walls);raised blood pressure (130/85 mmHg or higher); insulin resistance orglucose intolerance (the body can't properly use insulin or bloodsugar); prothrombotic state (e.g., high fibrinogen or plasminogenactivator inhibitor [−1] in the blood); and a proinflammatory state(e.g., elevated high-sensitivity C-reactive protein in the blood).

The underlying causes of this syndrome are overweight/obesity, physicalinactivity and genetic factors. People with metabolic syndrome are atincreased risk of coronary heart disease, other diseases related toplaque buildups in artery walls (e.g., stroke and peripheral vasculardisease) and type 2 diabetes.

Metabolic syndrome is closely associated with a generalized metabolicdisorder called insulin resistance, in which the body can't use insulinefficiently. This is why the metabolic syndrome is also called theinsulin resistance syndrome.

Some people are genetically predisposed to insulin resistance. Acquiredfactors, such as excess body fat and physical inactivity, can elicitinsulin resistance and the metabolic syndrome in these people. Mostpeople with insulin resistance have central obesity. The biologicmechanisms at the molecular level between insulin resistance andmetabolic risk factors aren't fully understood and appear to be complex.

The compositions comprising a compound of the invention are thereforeuseful in treating or preventing metabolic syndrome and disorders andrisk factors associated with metabolic syndrome.

Treatment or Prevention of Diabetes

As used herein, “treatment or prevention of diabetes” encompassestreatment or prevention of a complication associated with type IIdiabetes including, but not limited to, retinopathy (i.e., blindness);neuropathy (i.e., nerve damage) which leads to foot ulcers, gangrene,and amputations; kidney damage, which leads to dialysis; andcardiovascular disease. In some embodiments, the type II diabetes isassociated with abnormal/altered lyn kinase activity and/or expression.

Type II diabetes is associated with obesity and with aging. It is alifestyle-dependent disease, and has a strong genetic component(concordance in twins is 80-90%). The problem seems not so much ininsulin production, but that when the insulin reaches its target cells,it doesn't work correctly. Most Type II diabetes patients initially havehigh insulin levels along with high blood sugar. However, since sugarsignals the pancreas to release insulin, Type II diabetics eventuallybecome resistant to that signal and the endocrine-pancreas soon will notmake enough insulin. These people end up managing the disease withinsulin and they need much higher doses because they are resistant toit.

When a person takes in a high load of sugar, the sugar stimulates thepancreas to release insulin. The targets for insulin are muscle, fat,and liver cells. These cells have insulin receptor sites on the outsideof the cell membrane. For most people, when insulin has bound to thereceptors, a cascade of events begins, which leads to sugar beingtransported from the blood into the interior of the cell. In Type IIdiabetics, even when insulin is present on the cell membrane, theprocess doesn't work. The glucose is never taken up into the cell andremains in the bloodstream.

The liver is responsible for glucose production and insulin is theregulatory agent of production. A high blood sugar content causes thepancreas to release insulin, and the insulin should signal the liver tostop making sugars. But, in diabetics, there's resistance to that signaland the liver keeps producing glucose. Hyperglycemia leads to glucosetoxicity.

It is not high blood sugar that is the disease process of diabetes, butcomplications from the high blood sugar. A major problem faced bydoctors is that some people with high blood sugar feel fine; it's hardto treat diseases that are asymptomatic since most people don't want totake a pill for something that they do not feel bad about. Thecompositions comprising a compound of the invention are therefore usefulin treating or preventing type II diabetes or complications arising fromtype II diabetes and disorders and risk factors associated withmetabolic syndrome. Complications of diabetes include, but are notlimited to, diabetic neuropathy, diabetic retinopathy, erectiledysfunction, and kidney disease and the compounds of the invention areuseful in treating or preventing these complications.

Treatment or Prevention of Obesity

As used herein, “treatment or prevention of obesity” encompassestreatment or prevention of a complication associated with obesity.Complications of obesity include, but are not limited to,hypercholesterolemia, hypertension, dyslipidemia (for example, hightotal cholesterol or high levels of triglycerides), type 2 diabetes,coronary heart disease, stroke, gallbladder disease, osteoarthritis,sleep apnea and respiratory problems, and some cancers (endometrial,breast, and colon). In some embodiments, the obesity is associated withabnormal/altered lyn kinase activity and/or expression

Other Diseases for Treatment or Prevention

The present invention provides methods for the treatment or preventionof septicemia, thrombotic disorders, pancreatitis, hypertension,inflammation, and impotence, comprising administering to a patient atherapeutically effective amount of a composition comprising a compoundof the invention and a pharmaceutically acceptable vehicle. In someembodiments, these disorders are associated with abnormal/altered lynkinase activity and/or expression

As used herein, “treatment or prevention of septicemia” encompassestreatment or prevention of septic shock.

As used herein, “treatment or prevention of thrombotic disorders”encompasses treatment or prevention of high blood levels of fibrinogenand promotion of fibrinolysis.

In addition to treating or preventing obesity, the compositions of theinvention can be administered to an individual to promote weightreduction of the individual.

Therapeutic/Prophylactic Administration and Compositions

Due to the activity of the compounds of the invention, the compounds areadvantageously useful in veterinary and human medicine. As described inSection 5.3 above, the compounds of the invention are useful for thetreatment or prevention of cardiovascular diseases, dyslipidemias,dyslipoproteinemias, glucose metabolism disorders, metabolic syndrome(i.e., Syndrome X), PPAR-associated disorders, septicemia, thromboticdisorders, type II diabetes, obesity, pancreatitis, hypertension, renaldisease, inflammation, and impotence. In some embodiments, the subjecthas abnormal/altered lyn kinase activity and/or expression but does notexhibit or manifest any physiological symptoms associated with alyn-kinase-related disease.

The invention provides methods of treatment and prophylaxis byadministration to a patient of a therapeutically effective amount of acomposition comprising a compound of the invention. The patient is amammal, including, but not limited, to an animal such a cow, horse,sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guineapig, etc., and is more preferably a human.

The present compositions, which comprise one or more compounds of theinvention, are preferably administered orally. The compounds of theinvention may also be administered by any other convenient route, forexample, by infusion or bolus injection, by absorption throughepithelial or mucocutaneous linings (e.g., oral mucosa, rectal andintestinal mucosa, etc.) and may be administered together with anotherbiologically active agent. Administration can be systemic or local.Various delivery systems are known, e.g., encapsulation in liposomes,microparticles, microcapsules, capsules, etc., and can be used toadminister a compound of the invention. In certain embodiments, morethan one compound of the invention is administered to a patient. Methodsof administration include but are not limited to intradermal,intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,epidural, oral, sublingual, intranasal, intracerebral, intravaginal,transdermal, rectally, by inhalation, or topically, particularly to theears, nose, eyes, or skin. The preferred mode of administration is leftto the discretion of the practitioner, and will depend in-part upon thesite of the medical condition. In most instances, administration willresult in the release of the compounds of the invention into thebloodstream.

In specific embodiments, it may be desirable to administer one or morecompounds of the invention locally to the area in need of treatment.This may be achieved, for example, and not by way of limitation, bylocal infusion during surgery, topical application, e.g., in conjunctionwith a wound dressing after surgery, by injection, by means of acatheter, by means of a suppository, or by means of an implant, saidimplant being of a porous, non-porous, or gelatinous material, includingmembranes, such as sialastic membranes, or fibers. In one embodiment,administration can be by direct injection at the site (or former site)of an atherosclerotic plaque tissue.

Pulmonary administration can also be employed, e.g., by use of aninhaler or nebulizer, and formulation with an aerosolizing agent, or viaperfusion in a fluorocarbon or synthetic pulmonary surfactant. Incertain embodiments, the compounds of the invention can be formulated asa suppository, with traditional binders and vehicles such astriglycerides.

In another embodiment, the compounds of the invention can be deliveredin a vesicle, in particular a liposome (see Langer, 1990, Science249:1527-1533; Treat et al., in Liposomes in the Therapy of InfectiousDisease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York,pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generallyibid.).

In yet another embodiment, the compounds of the invention can bedelivered in a controlled release system. In one embodiment, a pump maybe used (see Langer, supra; Sefton, 1987, CRC Crit. Ref Biomed. Eng.14:201; Buchwald et al., 1980, Surgery 88:507 Saudek et al., 1989, N.Engl. J. Med. 321:574). In another embodiment, polymeric materials canbe used (sec Medical Applications of Controlled Release, Langer and Wise(eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled DrugBioavailability, Drug Product Design and Performance, Smolen and Ball(eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol.Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989,J. Neurosurg. 71:105). In yet another embodiment, a controlled-releasesystem can be placed in proximity of the target of the compounds of theinvention, e.g., the liver, thus requiring only a fraction of thesystemic dose (see, e.g., Goodson, in Medical Applications of ControlledRelease, supra, vol. 2, pp. 115-138 (1984)). Other controlled-releasesystems discussed in the review by Langer, 1990, Science 249:1527-1533)may be used.

The present compositions will contain a therapeutically effective amountof a compound of the invention, optionally more than one compound of theinvention, preferably in purified form, together with a suitable amountof a pharmaceutically acceptable vehicle so as to provide the form forproper administration to the patient.

In a specific embodiment, the term “pharmaceutically acceptable” meansapproved by a regulatory agency of the Federal or a state government orlisted in the U.S. Pharmacopeia or other generally recognizedpharmacopeia for use in animals, and more particularly in humans. Theterm “vehicle” refers to a diluent, adjuvant, excipient, or carrier withwhich a compound of the invention is administered. Such pharmaceuticalvehicles can be liquids, such as water and oils, including those ofpetroleum, animal, vegetable or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like. The pharmaceuticalvehicles can be saline, gum acacia, gelatin, starch paste, talc,keratin, colloidal silica, urea, and the like. In addition, auxiliary,stabilizing, thickening, lubricating and coloring agents may be used.When administered to a patient, the compounds of the invention andpharmaceutically acceptable vehicles are preferably sterile. Water is apreferred vehicle when the compound of the invention is administeredintravenously. Saline solutions and aqueous dextrose and glycerolsolutions can also be employed as liquid vehicles, particularly forinjectable solutions. Suitable pharmaceutical vehicles also includeexcipients such as starch, glucose, lactose, sucrose, gelatin, malt,rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate,talc, sodium chloride, dried skim milk, glycerol, propylene, glycol,water, ethanol and the like. The present compositions, if desired, canalso contain minor amounts of wetting or emulsifying agents, or pHbuffering agents.

The present compositions can take the form of solutions, suspensions,emulsion, tablets, pills, pellets, capsules, capsules containingliquids, powders, sustained-release formulations, suppositories,emulsions, aerosols, sprays, suspensions, or any other form suitable foruse. In one embodiment, the pharmaceutically acceptable vehicle is acapsule (see e.g., U.S. Pat. No. 5,698,155). Other examples of suitablepharmaceutical vehicles are described in Remington's PharmaceuticalSciences, A. R. Gennaro (Editor) Mack Publishing Co.

In a preferred embodiment, the compounds of the invention are formulatedin accordance with routine procedures as a pharmaceutical compositionadapted for intravenous administration to human beings. Typically,compounds of the invention for intravenous administration are solutionsin sterile isotonic aqueous buffer. Where necessary, the compositionsmay also include a solubilizing agent. Compositions for intravenousadministration may optionally include a local anesthetic such aslidocaine to ease pain at the site of the injection. Generally, theingredients are supplied either separately or mixed together in unitdosage form, for example, as a dry lyophilized powder or water freeconcentrate in a hermetically sealed container such as an ampoule orsachette indicating the quantity of active agent. Where the compound ofthe invention is to be administered by infusion, it can be dispensed,for example, with an infusion bottle containing sterile pharmaceuticalgrade water or saline. Where the compound of the invention isadministered by injection, an ampoule of sterile water for injection orsaline can be provided so that the ingredients may be mixed prior toadministration.

It is preferred that the compositions of the invention be administeredorally. Compositions for oral delivery may be in the form of tablets,lozenges, aqueous or oily suspensions, granules, powders, emulsions,capsules, syrups, or elixirs, for example. Orally administeredcompositions may contain one or more optionally agents, for example,sweetening agents such as fructose, aspartame or saccharin; flavoringagents such as peppermint, oil of wintergreen, or cherry: coloringagents; and preserving agents, to provide a pharmaceutically palatablepreparation. Moreover, where in tablet or pill form, the compositionsmay be coated to delay disintegration and absorption in thegastrointestinal tract thereby providing a sustained action over anextended period of time. Selectively permeable membranes surrounding anosmotically active driving compound are also suitable for orallyadministered compounds of the invention. In these later platforms, fluidfrom the environment surrounding the capsule is imbibed by the drivingcompound, which swells to displace the agent or agent compositionthrough an aperture. These delivery platforms can provide an essentiallyzero order delivery profile as opposed to the spiked profiles ofimmediate release formulations. A time delay material such as glycerolmonostearate or glycerol stearate may also be used. Oral compositionscan include standard vehicles such as mannitol, lactose, starch,magnesium stearate, sodium saccharine, cellulose, magnesium carbonate,etc. Such vehicles are preferably of pharmaceutical grade.

The amount of a compound of the invention that will be effective in thetreatment of a particular disorder or condition disclosed herein willdepend on the nature of the disorder or condition, and can be determinedby standard clinical techniques. In addition, in vitro or in vivo assaysmay optionally be employed to help identify optimal dosage ranges. Theprecise dose to be employed in the compositions will also depend on theroute of administration, and the seriousness of the disease or disorder,and should be decided according to the judgment of the practitioner andeach patient's circumstances. However, suitable dosage ranges for oraladministration are generally about 0.001 milligram to 200 milligrams ofa compound of the invention per kilogram body weight. In specificpreferred embodiments of the invention, the oral dose is 0.01 milligramto 70 milligrams per kilogram body weight, more preferably 0.1 milligramto 50 milligrams per kilogram body weight, more preferably 0.5 milligramto 20 milligrams per kilogram body weight, and yet more preferably 1milligram to 10 milligrams per kilogram body weight. In a most preferredembodiment, the oral dose is 5 milligrams of a compound of the inventionper kilogram body weight. The dosage amounts described herein refer tototal amounts administered; that is, if more than one compound of theinvention is administered, the preferred dosages correspond to the totalamount of the compounds of the invention administered. Oral compositionspreferably contain 10% to 95% active ingredient by weight.

Suitable dosage ranges for intravenous (i.v.) administration are 0.01milligram to 100 milligrams per kilogram body weight, 0.1 milligram to35 milligrams per kilogram body weight, and 1 milligram to 10 milligramsper kilogram body weight. Suitable dosage ranges for intranasaladministration are generally about 0.01 pg/kg body weight to 1 mg/kgbody weight. Suppositories generally contain 0.01 milligram to 50milligrams of a compound of the invention per kilogram body weight andcomprise active ingredient in the range of 0.5% to 10% by weight.Recommended dosages for intradermal, intramuscular, intraperitoneal,subcutaneous, epidural, sublingual, intracerebral, intravaginal,transdermal administration or administration by inhalation are in therange of 0.001 milligram to 200 milligrams per kilogram of body weight.Suitable doses of the compounds of the invention for topicaladministration are in the range of 0.001 milligram to 1 milligram,depending on the area to which the compound is administered. Effectivedoses may be extrapolated from dose-response curves derived from invitro or animal model test systems. Such animal models and systems arewell known in the art.

The invention also provides pharmaceutical packs or kits comprising oneor more containers filled with one or more compounds of the invention.Optionally associated with such container(s) can be a notice in the formprescribed by a governmental agency regulating the manufacture, use orsale of pharmaceuticals or biological products, which notice reflectsapproval by the agency of manufacture, use or sale for humanadministration. In a certain embodiment, the kit contains more than onecompound of the invention. In another embodiment, the kit comprises acompound of the invention and another lipid-mediating compound,including but not limited to a statin, a thiazolidinedione, or afibrate.

The compounds of the invention are preferably assayed in vitro and invivo, for the desired therapeutic or prophylactic activity, prior to usein humans. For example, in vitro assays can be used to determine whetheradministration of a specific compound of the invention or a combinationof compounds of the invention is preferred for lowering fatty acidsynthesis. The compounds of the invention may also be demonstrated to beeffective and safe using animal model systems.

Other methods will be known to the skilled artisan and are within thescope of the invention.

Combination Therapy

In certain embodiments of the invention, the compounds of the inventioncan be used in combination therapy with at least one other therapeuticagent. The compound of the invention and the therapeutic agent can actadditively or, more preferably, synergistically. In a preferredembodiment, a composition comprising a compound of the invention isadministered concurrently with the administration of another therapeuticagent, which can be part of the same composition as the compound of theinvention or a different composition. In another embodiment, acomposition comprising a compound of the invention is administered prioror subsequent to administration of another therapeutic agent. As many ofthe disorders for which the compounds of the invention are useful intreating are chronic disorders, in one embodiment combination therapyinvolves alternating between administering a composition comprising acompound of the invention and a composition comprising anothertherapeutic agent, e.g., to minimize the toxicity associated with aparticular drug. The duration of administration of each drug ortherapeutic agent can be, e.g., one month, three months, six months, ora year. In certain embodiments, when a composition of the invention isadministered concurrently with another therapeutic agent thatpotentially produces adverse side effects including but not limited totoxicity, the therapeutic agent can advantageously be administered at adose that falls below the threshold at which the adverse side iselicited.

The present compositions can be administered together with a statin.Statins for use in combination with the compounds of the inventioninclude but are not limited to atorvastatin, pravastatin, fluvastatin,lovastatin, simvastatin, and cerivastatin.

The present compositions can also be administered together with a PPARagonist, for example a thiazolidinedione or a fibrate.Thiazolidinediones for use in combination with the compounds of theinvention include but are not limited to5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione,troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD5075, darglitazone, and rosiglitazone. Fibrates for use in combinationwith the compounds of the invention include but are not limited togemfibrozil, fenofibrate, clofibrate, or ciprofibrate. As mentionedpreviously, a therapeutically effective amount of a fibrate orthiazolidinedione often has toxic side effects. Accordingly, in apreferred embodiment of the present invention, when a composition of theinvention is administered in combination with a PPAR agonist, the dosageof the PPAR agonist is below that which is accompanied by toxic sideeffects.

The present compositions can also be administered together with abile-acid-binding resin. Bile-acid-binding resins for use in combinationwith the compounds of the invention include but are not limited tocholestyramine and colestipol hydrochloride.

The present compositions can also be administered together with niacinor nicotinic acid.

The present compositions can also be administered together with a RXRagonist. RXR agonists for use in combination with the compounds of theinvention include but are not limited to LG 100268, LGD 1069, 9-cisretinoic acid,2-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl)-pyridine-5-carboxylicacid, or4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)2-carbonyl)-benzoicacid.

The present compositions can also be administered together with ananti-obesity drug. Anti-obesity drugs for use in combination with thecompounds of the invention include but are not limited to β-adrenergicreceptor agonists, preferably β-3 receptor agonists, sibutramine,bupropion, fluoxetine, and phentermine.

The present compositions can also be administered together with ahormone. Hormones for use in combination with the compounds of theinvention include but are not limited to thyroid hormone, estrogen andinsulin. Preferred insulins include but are not limited to injectableinsulin, transdermal insulin, inhaled insulin, or any combinationthereof. As an alternative to insulin, an insulin derivative,secretagogue, sensitizer or mimetic may be used. Insulin secretagoguesfor use in combination with the compounds of the invention include butare not limited to forskolin, dibutryl cAMP or isobutylmethylxanthine(IBMX).

The present compositions can also be administered together with atyrophostine or an analog thereof. Tyrophostines for use in combinationwith the compounds of the invention include but are not limited totryophostine 51.

The present compositions can also be administered together withsulfonylurma-based drugs. Sulfonylurea-based drugs for use incombination with the compounds of the invention include, but are notlimited to, glisoxepid, glyburide, acetohexamide, chlorpropamide,glibornuride, tolbutamide, tolazamide, glipizide, gliclazide,gliquidone, glyhexamide, phenbutamide, and tolcyclamide.

The present compositions can also be administered together with abiguanide. Biguanides for use in combination with the compounds of theinvention include but are not limited to metformin, phenformin andbuformin.

The present compositions can also be administered together with anα-glucosidase inhibitor. α-glucosidase inhibitors for use in combinationwith the compounds of the invention include but are not limited toacarbose and miglitol.

The present compositions can also be administered together with an apoA-I agonist. In one embodiment, the apo A-I agonist is the Milano formof apo A-I (apo A-IM). In a preferred mode of the embodiment, the apoA-IM for administration in conjunction with the compounds of theinvention is produced by the method of U.S. Pat. No. 5,721,114 toAbrahamsen. In a more preferred embodiment, the apo A-I agonist is apeptide agonist. In a preferred mode of the embodiment, the apo A-Ipeptide agonist for administration in conjunction with the compounds ofthe invention is a peptide of U.S. Pat. No. 6,004,925 or 6,037,323 toDasseux.

The present compositions can also be administered together withapolipoprotein E (apo E). In a preferred mode of the embodiment, theapoE for administration in conjunction with the compounds of theinvention is produced by the method of U.S. Pat. No. 5,834,596 toAgeland.

In yet other embodiments, the present compositions can be administeredtogether with an HDL-raising drug; an HDL enhancer; or a regulator ofthe apolipoprotein A-I, apolipoprotein A-IV and/or apolipoprotein genes.

Combination Therapy with Cardiovascular Drugs

The present compositions can be administered together with a knowncardiovascular drug. Cardiovascular drugs for use in combination withthe compounds of the invention to prevent or treat cardiovasculardiseases include but are not limited to peripheral anti-adrenergicdrugs, centrally acting antihypertensive drugs (e.g., methyldopa,methyldopa HCl), antihypertensive direct vasodilators (e.g., diazoxide,hydralazine HCl), drugs affecting renin-angiotensin system, peripheralvasodilators, phentolamine, antianginal drugs, cardiac glycosides,inodilators (e.g., amrinone, milrinone, enoximone, fenoximone, imazodan,sulmazole), antidysrhythmic drugs, calcium entry blockers, ranitine,bosentan, and rezulin.

Combination Therapy for Cancer Treatment

The present compositions can be administered together with treatmentwith irradiation or one or more chemotherapeutic agents. For irradiationtreatment, the irradiation can be gamma rays or X-rays. For a generaloverview of radiation therapy, see Hellman, Chapter 12: Principles ofRadiation Therapy Cancer, in: Principles and Practice of Oncology,DeVita et al., eds., 2^(nd). Ed., J.B. Lippencott Company, Philadelphia.Useful chemotherapeutic agents include methotrexate, taxol,mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide,ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin,dacarbazine, procarbizine, etoposides, campathecins, bleomycin,doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin,mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine,paclitaxel, and docetaxel. In a specific embodiment, a composition ofthe invention further comprises one or more chemotherapeutic agentsand/or is administered concurrently with radiation therapy. In anotherspecific embodiment, chemotherapy or radiation therapy is administeredprior or subsequent to administration of a present composition,preferably at least an hour, five hours, 12 hours, a day, a week, amonth, more preferably several months (e.g., up to three months),subsequent to administration of a composition of the invention.

Examples

Type II diabetes is characterized by high blood glucose levels in thepresence of normal amounts of insulin. Animal models of type II diabetesinvolve administering high levels of glucose and measuring blood glucoselevels and the ability of the experimental animal to maintain glucosehomeostasis over time. Several pharmacological structural classes caneffectively regulate this hyperglycemic response includingsulfonylureas, thiazoladinediones (PPARγ agonists; glitazones) ormetformin (glucophage). These drug classes are also clinically approvedfor use in humans. In the current study, we established a mouse model ofhyperglycemia by administering high levels of glucose to mice. Wevalidated this as a model of type 11 diabetes by demonstrating thatmetformin can effectively reduce the blood glucose load. We demonstratethat Compound 102 and Compound 105, which are illustrative examples ofcompounds of the invention, are effective in reducing blood glucoselevels in this model of type II diabetes.

Example 1: Oral Glucose Tolerance Test

Glucose was formulated in water at a concentration of 150 mg/ml anddosed at a volume of 10 ml/kg to produce a dose of 1.5 g/kg. Glucose wasmeasured using the Ascensia II Elite XL glucose monitor (Bayer). Measureglucose by taking a small (2 mm) section off the tip of the tail, bleedonto glucose test strip and measure. Data for each time point analyzedby ANOVA and post-hoc Tukey's test. A p value of less then 0.05 was usedto indicate statistical significance.

Two studies were conducted with the following Compound 102.

In study 1, mice were dosed with Compound 102 and glucose as follows:

Time (minutes) Treatment/measure 0 Drug or vehicle 15 Glucose measure 30Administer oral glucose 45 Glucose measure 60 Glucose measure 90 Glucosemeasure 120 Glucose measure

In study 2, mice were dosed with Compound 102 and glucose as follows.

Time (minutes) Treatment/measure 0 Administer Drug 15 Glucose measure 30Drug or vehicle 30 Administer oral glucose 45 Glucose measure 60 Drug orvehicle 75 Glucose measure 90 Drug or vehicle 120 Glucose measure 150Glucose measure

Study 3 tested Compound 102 and was conducted as follows:

Time (minutes) Treatment/measure 0 Drug or vehicle 15 Glucose measure 30Administer oral glucose 45 Glucose measure 60 Glucose measure 90 Glucosemeasure 120 Glucose measure

In study 1, a single administration of Compound 102 at a dose of 30mg/kg significantly decreased normal blood glucose levels (pre-glucoseloading) and significantly attenuated the blood glucose levels producedby oral glucose administration. Significance was lost 90 minutes afterdrug administration.

In study 2, with increased dosing, Compound 102 produced a more dramaticeffect on blood glucose levels.

Compound 105 also produced dramatic reductions in blood glucose levels.A single dose of 2 or 10 mg/kg significantly (P<0.05) reduced bloodglucose levels at all time points after administration. Baseline bloodglucose levels were also significantly depressed. Data are shown in FIG.3.

Example 2: Western Diet

Male CD1/1CR mice were obtained from Harlan. The study was started whenmice were 8 weeks of age. Prior to initiation of the study mice fastedfor 24 hrs. Mice were fed “Western Diet” that was designed toapproximate the “typical” human diet of North America and Europe(Research Diets; New Brunswick, N.J.; Western Diet composition). TheWestern Diet contained greater then 5 times more fat then normal chow.

Compound 102. Diet Compositions Western Diet Normal Diet gm % gm %Protein 20 16 Carbohydrate 50 61 Fat 21 4 kcal/gm 4.7 3.2

Mice were weighed daily beginning from the start of the 24 hr fastingperiod. Food intake was monitored continuously. Mice were bled byretroorbital eyebleed on days 7, 14, 21 and 28 after the initiation ofthe study. On day of REB mice were dosed 1× with full dose 1 hr prior tobleed. Fat pads were dissected at the end of the study (day 31) weighedand frozen. The following fat pads were dissected: brown, inguinal,axial, mesenteric, renal and epididymal. Data were averaged and analyzedby ANOVA followed by a post-hoc Tukey's test with a p value of less then0.05 indicating a statistical difference.

Administration of Compound 102 significantly reduced weight gain at thehighest dose tested (30 mg/kg/day). This effect was apparent whenmeasuring absolute weight (FIG. 1) and also when measuring weight changefrom day 0 (FIG. 2). Food intake was not affected by Compound 102administration (FIG. 3).

Fat pads weights were significantly elevated in Western diet animals ascompared to normal chow fed animals. Compound 102 administrationsignificantly reduced brown, axial, inguinal, renal and epididymal fatpad increases, but not mesenteric levels (FIG. 4)

Administration of Compound 102 produced a significant alteration inweight change in western diet fed animals that was independent of aneffect on food intake and that was associated with reduction in fat paddevelopment.

Example 3: Leptin Levels in Western Diet Treated Animals

Blood from mice that were on western diet (Compound 102) were analyzedfor leptin levels. Mice were bled by retroorbital eyebleed on days 7,14, 21 and 28 after the initiation of the study. On day of REB mice weredosed once with full dose 1 hr prior to bleed. Leptin levels weredetermined by ELISA (R&D Systems) as per directions. Data are expressedas the average±SEM. Data were averaged and analyzed by ANOVA followed bya post-hoc Tukey's test with a p value of less then 0.05 indicating astatistical difference.

Western diet led to a significant reduction in blood leptin levels asearly as one week after initiation of the study. These leptin levelswere not different from leptin levels of animals fed a normal diet.Administration of Compound 102 to animals fed a western diet reducedleptin levels to those fed a normal diet. This reduction may reflect adecrease in fat pad development and may be secondary to this event.

These data taken together with the data on weight gain, food intake andfat pad development indicate that animals fed a western diet and treatedwith Compound 102 do not look different from those fed a normal diet.

Example 4: In Vivo Db/Db Mouse Study

Db/Db and Db/lean mice were obtained from Harlan at 6 weeks of age. Micewere housed 3 per cage and fed ad libitum normal rodent chow. Mice werekept on a 12 hr Light:dark cycle.

The study was initiated when mice reached an age of 8 weeks and theirbaseline blood glucose levels were greater than 200 mg/dl. Compound 102was formulated in PBS: 2N HCl (99:1) at concentrations of 0.5, 1.5 and 5mg/ml. Mice were dosed at volumes of 10 ml/kg to produce doses of 5, 15and 50 mg/kg/dose. Mice were dosed twice per day at an 8 hr interval (8am and 4 pm) during the light cycle.

Glucose Study

For the acute blood glucose measurements, blood glucose levels weremeasured after the animals received their first dose of Compound 102.Blood glucose levels were measured two hrs after this initial injection.

Obesity Study

Mice were administered vehicle or drug (i.e., Compound 102) (5, 15, and50 mg/kg) twice per day (bid) for the 28 days. Mouse weight and foodintake were monitored daily. Food intake is reported as food intake(grams) per mouse per 24 hr period.

Glucose Results

In a Db/Db Leptin Receptor deficient diabetes/metabolic syndrome animalmodel, Compound 102 exhibited a dose dependent effect on both animalweight gain and blood glucose levels. In this study, mice were dosedwith Compound 102 IP, twice/day over the course of four weeks.Significantly different animal weights were observed between Db/Dbvehicle treated mice and mice receiving Compound 102 at doses of 5mg/kg, 15 mg/kg (p<0.05) and 50 mg/kg (p<0.01). Compound 102 has alsobeen shown to reduce blood glucose levels following acuteadministration. Animals also demonstrated an acute dose response in the15 mg/kg and 50 mg/kg dose groups upon study initiation and on weeklyblood glucose testing.

Obesity Results

When chronically administered to mice, Compound 102 significantlyinhibited a weight-gain response to animals fed a high fat diet. Thereis no obvious trivial explanation for this effect. Most importantly,animals demonstrated normal food intake compared to vehicle-treatedanimals. Also, animals defecated normally and did not display thehyperactivity normally associated with the amphetamine class ofweight-loss drugs.

Example 5: In Vivo Zucker Rat Study

Zucker rats and corresponding lean rats were supplied by Harlan. Ratswere fed a normal diet, ad libitum, and kept on a 12 hr light/darkcycle. Rats were housed 3 per cage.

Glucose Study

At 12 weeks of age, Zucker rats were administered Compound 102 at aconcentration of 30 mg/kg (ip). Blood glucose levels were measured 30minutes after administration. Forty-five minutes after drugadministration, animals were administered a glucose solution (1.5 g/kg)by oral gavage. Blood glucose levels were measured every 30 minutesafter gavage for 4.5 hrs.

There were 3 groups with 3 animals per group: 1) 3 Zucker leans (nodrug; no glucose treatment); 2) Zucker vehicle treated group (glucosechallenged and 3) Zucker Compound 102 treatment (30 mg/kg); glucosechallenged.

Glucose Results

Oral glucose administration produced an elevation of blood glucoselevels at two time points after administration: 30 and 270 minutes.Administration of Compound 102 reduced blood glucose levels at both timepoints.

The present invention is not to be limited in scope by the specificembodiments disclosed in the examples which are intended asillustrations of a few aspects of the invention and any embodimentswhich are functionally equivalent are within the scope of thisinvention. Indeed, various modifications of the invention in addition tothose shown and described herein will become apparent to those skilledin the art and are intended to fall within the appended claims.

A number of references have been cited, the entire disclosures of whichare incorporated herein by reference.

1-20. (canceled)
 21. A method of treating gestational diabetes mellitus(GDM) or maturity onset diabetes of the young (MODY) in a mammalcomprising administering to the mammal in need thereof a compound offormula:

wherein: R¹ is an alkyl group; X is a halogen; Y is O, S, or NH; Z is Oor S; and n is an integer from 0 to 5 and m is 0 or 1, wherein m+n isless than or equal to 5, or a pharmaceutically acceptable salt thereof.22. The method of claim 21, wherein the compound is a compound offormula

wherein: R¹ is an alkyl group; X is a halogen; and n is an integer from0 to 5 and m is 0 or 1, wherein m+n is less than or equal to
 5. 23. Themethod of claim 21, wherein the compound is a compound of formula

wherein: R¹ is an alkyl group; and n is an integer from 0 to
 5. 24. Themethod of claim 21, wherein the compound is a compound of formula


25. The method of claim 21, wherein the compound is a compound offormula

wherein: X is a halogen; and m is an integer from 0 to
 1. 26. The methodof claim 21, wherein the compound is a compound of formula


27. The method of claim 21, wherein the compound is administered orally.28. The method of claim 27, wherein the amount of the compoundadministered orally is 0.5 mg to 20 mg per kilogram of body weight. 29.The method of claim 21, wherein the compound is administeredintravenously.
 30. The method of claim 29, wherein the amount of thecompound administered intravenously is 0.1 mg to 35 mg per kilogram ofbody weight.
 31. The method of claim 21, wherein the compound isadministered intranasally.
 32. The method of claim 31, wherein theamount of the compound administered intranasally is 0.01 pg to 1 mg perkilogram of body weight.
 33. The method of claim 21, wherein thecompound is administered concurrently with the administration of anothertherapeutic agent.
 34. The method of claim 33, wherein the anothertherapeutic agent is chosen from a statin, a PPAR agonist, abile-acid-binding resin, niacin, nicotinic acid, a RXR agonist, ananti-obesity drug, a hormone, an insulin secretagog, a tyrophostine, asulfonylurea-based drug, metformin, an α-glucosidase inhibitor, an apoA-I agonist, apolipoprotein E, a cardiovascular drug, and achemotherapeutic agent.
 35. The method of claim 34, wherein: the statinis chosen from atorvastatin, pravastatin, fluvastatin, lovastatin,simvastatin, and cerivastatin; the PPAR agonist is chosen fromtroglitazone, pioglitazone, rosiglitazone, ciglitazone,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione,AD 5075, WAY-120,744, englitazone, darglitazone, gemfibrozil,fenofibrate, clofibrate, and ciprofibrate; the bile-acid-binding resinis chosen from cholestyramine and colestipol hydrochloride; the RXRagonist is chosen from LG 100268, LGD 1069, 9-cis retinoic acid,2-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl)-pyridine-5-carboxylicacid, and4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)2-carbonyl)-benzoicacid; the anti-obesity drug is chosen from 0-3 receptor agonists,sibutramine, bupropion, fluoxetine, and phentermine; the hormone ischosen from thyroid hormone, estrogen and insulin; the insulinsecretagog is chosen from forskolin, dibutryl cAMP, andisobutylmethylxanthine; the tyrophostine is tryophostine 51; thesulfonylurea-based drug is chosen from glisoxepid, glyburide,acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide,glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, andtolcyclamide; the α-glucosidase inhibitor is chosen from acarbose andmiglitol; the apo A-I agonist is the Milano form of apo A-I (apo A-IM);the cardiovascular drug is chosen from methyldopa, diazoxide,hydralazine, phentolamine, amrinone, milrinone, enoximone, fenoximone,imazodan, sulmazole, ranitine, bosentan, and rezulin; and thechemotherapeutic agent is chosen from methotrexate, taxol,mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide,ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin,dacarbazine, procarbizine, etoposides, campathecins, bleomycin,doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin,mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine,paclitaxel, and docetaxel.
 36. The method of claim 33, wherein theanother therapeutic agent is insulin.
 37. The method of claim 36,wherein the insulin is injectable insulin, transdermal insulin, orinhaled insulin.
 38. The method of claim 21, wherein the mammal is ahuman.